Choongwae Enters Competitive Hyperlipidemia Treatment Market
Published: 2005-01-24 06:56:00
Updated: 2005-01-24 06:56:00
Choongwae Pharmaceutical enters the domestic hyperlipidemia treatment market valued over 100 billion won by obtaining the market approval for Livalo, an original drug co-developed by Japan's Kowa Yakuhin and Nissan Chemical Industries.
Launched in Japan in September 2003, Livalo (active ingred...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
